Josephine Torrente - 07 Oct 2021 Form 4 Insider Report for AGILE THERAPEUTICS INC

Role: Director
Signature: /s/ Geoffrey P. Gilmore, as Attorney-in Fact
Issuer symbol: N/A
Transactions as of: 07 Oct 2021
Net transactions value: $0
Form type: 4
Filing time: 08 Oct 2021, 17:03:52 UTC
Next filing: 10 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGRX	Common Stock	Award	$0	+79,593		$0.000000	79,593	07 Oct 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGRX	Employee Stock Option (Right to Buy)	Award	$0	+97,116		$0.000000	97,116	07 Oct 2021	Common Stock	97,116	$0.9423	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units that were granted on October 7, 2021, which will vest and be settled in common stock in three annual installments as follows: 26,537 shares on October 7, 2022, 26,528 shares on October 7, 2023, and 26,528 shares on October 7, 2024, subject to the Reporting Person's continued service on the Issuer's board of directors through each vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during each respective year of board service.
F2	The option was granted on October 7, 2021 and vests in three annual installments as follows: 32,379 shares on October 7, 2022, 32,369 shares on October 7, 2023, and 32,368 shares on October 7, 2024 subject to the Reporting Person's continued service on the Issuer's board of directors through each vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during each respective year of board service.

Content

These shares represent restricted stock units that were granted on October 7, 2021, which will vest and be settled in common stock in three annual installments as follows: 26,537 shares on October 7, 2022, 26,528 shares on October 7, 2023, and 26,528 shares on October 7, 2024, subject to the Reporting Person's continued service on the Issuer's board of directors through each vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during each respective year of board service.

The option was granted on October 7, 2021 and vests in three annual installments as follows: 32,379 shares on October 7, 2022, 32,369 shares on October 7, 2023, and 32,368 shares on October 7, 2024 subject to the Reporting Person's continued service on the Issuer's board of directors through each vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during each respective year of board service.